High-intensity statin therapy in patients with chronic kidney disease: A systematic review and meta-analysis

BMJ Open

Volumn 5, Issue 5, 2015, Pages

  Yan, Yu Ling ^a   Qiu, Bo ^a   Wang, Jing ^a   Deng, Song Bai ^a   Wu, Ling ^a   Jing, Xiao Dong ^a   Du, Jian Lin ^a   Liu, Ya Jie ^a   She, Qiang ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CERIVASTATIN; COMPACTIN; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ALBUMINURIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; MYOPATHY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SYSTEMATIC REVIEW; DRUG ADMINISTRATION; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; STROKE;

DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; STROKE;

EID: 84930009619     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006886     Document Type: Review

References (30)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69.
2. Pinkau T, Hilgers KF, Veelken R, et al. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? J Am Soc Nephrol 2004;15:517-23.
3. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascularevents, and hospitalization. N Engl J Med 2004;351:1296-305.
4. Jungers P, Massy ZA, Nguyen Khoa T, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 1997;12:2597-602.
5. Hyre AD, Fox CS, Astor BC, et al. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis 2007;49:37-45.
6. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
7. [No authors listed]. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
8. Heart protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
9. Mills EJ, O'Regan C, Eyawo O, et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. Eur Heart J 2011;32:1409-15.
10. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and metaregression of randomized controlled trials. BMJ 2008;336:645-51.
11. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157:263-75.
12. Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157:251-62.
13. Hou W, Lv J, Perkovic V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: asystematic review and meta-analysis. Eur Heart J 2013;34:1807-17.
14. Zhang X, Xiang C, Zhou YH, et al. Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. BMC Cardiovasc Disord 2014;14:19.
15. Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009;(2):CD007784.
16. Tonelli M, Wanner C, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med 2014;160:182.
17. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration, 2011.
18. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
19. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (treating to new targets) study. J Am Coll Cardiol 2008;51:1448-54.
20. Koren MJ, Davidson MH, Wilson DJ, et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis 2009;53:741-50.
21. Holme I, Fayyad R, Faergeman O, et al. Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. J Intern Med 2010;267:567-75.
22. Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justfication for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 2010;55:1266-73.
23. Rutter MK, Prais HR, Charlton-Menys V, et al. Protection against nephropathy in diabetes with atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. Low-dose atorvastatin. Diabetes Med 2011;28:100-8.
24. Amarenco P, Callahan A, Campese VM, et al. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke 2014;45:2974-82.
25. Pellicori P, Costanzo P, Joseph AC, et al. Medical management of stable coronary atherosclerosis. Curr Atheroscler Rep 2013;15:313.
26. Deedwania PC. Statins in chronic kidney disease: cardiovascular risk and kidney function. Postgrad Med 2014;126:29-36.
27. Drury PL, Ting R, Zannino D, et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovasular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54:32-43.
28. Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular factors and cardiovascular morbidity. J Intern Med 2001;249:519-26.
29. Nikolic D, Banach M, Nikfar S, et al. A meta-analysis of the role of statin on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol 2013;168:5437-47.
30. Yan YL, Qiu B, Hu LJ, et al. Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: a systematic review and meta-analysis. Eur J Clin Pharmacol 2013;69:2001-9.